本报告导读：公司2024 年收入整体符合预期，降本增效成果显著。呋喹替尼全球有望持续放量，赛沃替尼年内有望美国提交NDA，ATTC 平台管线值得期待。维持“增持”评级。投资要点：核心业务表现 亮眼，维持“增持”评级。公司2024年实现收入6.30 亿美元（-25%），其中0.67 亿美元为首付款、里程碑金及研发服务（23 年为3.46 亿美元），净收益为0.38 亿美元（-85%），截止2024 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.